Lifeward (NASDAQ:LFWD) Lowered to “Strong Sell” Rating by Zacks Research

Lifeward (NASDAQ:LFWD) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Wednesday,Zacks.com reports.

Several other analysts also recently issued reports on the stock. HC Wainwright boosted their target price on shares of Lifeward to $10.00 and gave the company a “buy” rating in a research note on Thursday, March 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lifeward in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $10.00.

Lifeward Stock Performance

Shares of LFWD opened at $7.17 on Wednesday. The company has a 50-day moving average of $6.92 and a two-hundred day moving average of $7.08. The stock has a market cap of $20.18 million, a price-to-earnings ratio of -0.36 and a beta of 0.36. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.40 and a quick ratio of 1.82. Lifeward has a one year low of $4.14 and a one year high of $15.00.

Lifeward (NASDAQ:LFWD) last released its quarterly earnings results on Friday, May 15th. The company reported ($6.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.18) by ($5.52). The firm had revenue of $3.92 million for the quarter, compared to analyst estimates of $5.78 million. Lifeward had a negative net margin of 123.66% and a negative return on equity of 243.14%. On average, equities research analysts expect that Lifeward will post -4.27 earnings per share for the current year.

Institutional Trading of Lifeward

A number of institutional investors have recently bought and sold shares of the company. HRT Financial LP increased its position in Lifeward by 149.7% in the 4th quarter. HRT Financial LP now owns 49,081 shares of the company’s stock worth $28,000 after purchasing an additional 29,423 shares during the last quarter. Virtu Financial LLC lifted its holdings in shares of Lifeward by 158.0% during the 4th quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock valued at $35,000 after buying an additional 37,037 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Lifeward by 77.3% in the 4th quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock valued at $40,000 after buying an additional 29,927 shares in the last quarter. Finally, Citadel Advisors LLC grew its stake in shares of Lifeward by 1,271.8% in the 3rd quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock valued at $152,000 after buying an additional 198,406 shares in the last quarter. Institutional investors and hedge funds own 26.76% of the company’s stock.

Key Stories Impacting Lifeward

Here are the key news stories impacting Lifeward this week:

• Negative Sentiment: HC Wainwright cut Lifeward’s 2026 earnings outlook sharply, now expecting a much larger loss per share for FY2026 than previously forecast. Lifeward analyst estimates
• Negative Sentiment: The firm also reduced Q2 2026, Q3 2026, and Q4 2026 EPS estimates, suggesting weaker profitability in the near term. Lifeward analyst estimates
• Negative Sentiment: HC Wainwright lowered longer-term EPS projections for FY2027, FY2028, and FY2029 as well, indicating a slower path to earnings recovery. Lifeward analyst estimates
• Neutral Sentiment: Despite the lower estimates, HC Wainwright kept a Buy rating and a $10 price target on Lifeward, implying the firm still sees upside from current levels. Lifeward analyst estimates
• Positive Sentiment: HC Wainwright raised its FY2030 EPS estimate, suggesting the company could eventually return to stronger profitability over the long term. Lifeward analyst estimates

Lifeward Company Profile

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.